Clinical 18F-FDG and Amyloid Brain Positron Emission Tomography/CT in the Investigation of Cognitive Impairment: Where Are We Now?

Clinical 18F-FDG and Amyloid Brain Positron Emission Tomography/CT in the Investigation of Cognitive Impairment: Where Are We Now?
Br J Radiol. 2019 Apr 14;:20181027
Authors: Dumba M, Khan S, Patel N, Perry L, Malhotra P, Perry R, Nijran K, Barwick T, Wallitt K, Win Z
Abstract
The number of people living with dementia is increasing, but as yet there remains no cure or disease-modifying treatment. This review aims to help readers understand the role of 18F-FDG PET/CT imaging in the investigation of cognitive impairment and how the advent of amyloid PET/CT imaging may hold the key to radically changing management of the most common form of dementia - Alzheimer's disease. The indications for 18F-FDG PET/CT and amyloid PET/CT imaging in cognitive impairment are outlined. Additionally, the mechanisms of action, technique, patient preparation and acquisition parameters for both are detailed. We conclude by providing a framework for interpreting 18F-FDG PET/CT and amyloid PET/CT imaging in the more common conditions that lead to cognitive impairment conditions with tips on avoiding pitfalls in interpretation.
PMID: 30982329 [PubMed - as supplied by publisher]

Source: The British Journal of Radiology - April 13, 2019 Category: Radiology Authors: Dumba M, Khan S, Patel N, Perry L, Malhotra P, Perry R, Nijran K, Barwick T, Wallitt K, Win Z Tags: Br J Radiol Source Type: research